IN8bio (NASDAQ:INAB) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of IN8bio (NASDAQ:INAB) in a report released on Wednesday morning,Benzinga reports. They currently have a $8.00 target price on the stock.

IN8bio Price Performance

NASDAQ:INAB opened at $0.29 on Wednesday. The stock has a fifty day moving average price of $0.28 and a 200-day moving average price of $0.36. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. IN8bio has a fifty-two week low of $0.22 and a fifty-two week high of $1.74.

IN8bio (NASDAQ:INAB) last released its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, research analysts forecast that IN8bio will post -0.56 earnings per share for the current year.

Institutional Trading of IN8bio

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its holdings in shares of IN8bio by 56.5% during the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after buying an additional 185,919 shares in the last quarter. Sigma Planning Corp raised its holdings in shares of IN8bio by 42.0% during the 3rd quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock worth $230,000 after buying an additional 251,600 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of IN8bio during the 4th quarter worth $1,465,000. AIGH Capital Management LLC raised its holdings in shares of IN8bio by 269.7% during the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after buying an additional 4,517,227 shares in the last quarter. Finally, BIOS Capital Management LP acquired a new position in shares of IN8bio during the 4th quarter worth $2,212,000. 92.05% of the stock is currently owned by institutional investors.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.